‘Advocacy groups are the connectors’: Experiences and contributions of rare disease patient organization leaders in advanced neurotherapeutics

Abstract

Introduction Biomedical progress has facilitated breakthrough advanced neurotherapeutic interventions, whose potential to improve outcomes in rare neurological diseases has increased hope among people with lived experiences and their carers. Nevertheless, gene, somatic cell and other advanced neurotherapeutic interventions carry significant risks. Rare disease patient organizations (RDPOs) may enhance patient experiences, inform expectations and promote health literacy. However, their perspectives are understudied in paediatric neurology. If advanced neurotherapeutics is to optimize RDPO contributions, it demands further insights into their roles, interactions and support needs. Methods We used a mixed‐methodology approach, interviewing 20 RDPO leaders representing paediatric rare neurological diseases and following them up with two online surveys featuring closed and open‐ended questions on advanced neurotherapeutics (19/20) and negative mood states (17/20). Qualitative and quantitative data were analysed using thematic discourse analysis and basic descriptive statistics, respectively. Results Leaders perceived their roles to be targeted at educational provision (20/20), community preparation for advanced neurotherapeutic clinical trials (19/20), information simplification (19/20) and focused research pursuits (20/20). Although most leaders perceived the benefits of collaboration between stakeholders, some cited challenges around collaborative engagement under the following subthemes: conflicts of interest, competition and logistical difficulties. Regarding neurotherapeutics, RDPO leaders identified support needs centred on information provision, valuing access to clinician experts and highlighting a demand for co‐developed, centralized, high‐level and understandable, resources that may improve information exchange. Leaders perceived a need for psychosocial support within themselves and their communities, proposing that this would facilitate informed decision‐making, reduce associated psychological vulnerabilities and maintain hope throughout neurotherapeutic development. Conclusion This study provides insights into RDPO research activities, interactions and resource needs. It reveals a demand for collaboration guidelines, central information resources and psychosocial supports that may address unmet needs and assist RDPOs in their advocacy. Patient or Public Contribution In this study, RDPO leaders were interviewed and surveyed to examine their perspectives and roles in advanced neurotherapeutic development. Some participants sent researchers postinterview clarification emails regarding their responses to questions.

‘High hopes for treatment’: Australian stakeholder perspectives of the clinical translation of advanced neurotherapeutics for rare neurological diseases

“…These findings have broad ramifications and resonate with the importance of knowledge exchange and partnerships described in an Asia-Pacific perspective on the facilitators and barriers to implementation of SMA gene therapy. 20 At the clinician-patient interface, as replicated in prior studies, the importance of a well-curated, accessible, contemporary and 'single source of truth' 21 has been recognised to address information needs in healthcare professionals and carers. While toolkits to improve therapeutic readiness, facilitate knowledge dissemination and inform decision-making have been built on a disease-specific basis, 22 establishing a consensus approach to management and therapeutic decision-making by concentrating on the shared pathways between heterogenous diseases may enable a broader view of advanced therapies within the context of RNDs across healthcare systems.…”

Resilience in patients and family caregivers living with congenital disorders of glycosylation (CDG): a quantitative study using the brief resilience coping scale (BRCS)

“…Rare diseases patients’ organizations (POs) also can empower family caregivers by building a community and connecting parents of affected children with common diagnoses or similar diseases with peers, healthcare professionals, and researchers, enhancing social and professional support [ 72 – 74 ]. POs can also play a crucial role by promoting health literacy [ 75 , 76 ], raising research funding, and speed up patient access to therapeutic care [ 75 ]. The CDG community can obtain informational support related to research, clinical trials, treatment options, epidemiology, care, and other areas on websites like CDG Hub [ 77 ], CDG Care [ 78 ], World CDG Organization [ 84 ], and ClinicalTrials.gov [ 80 ].…”

Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges

“…RD patients frequently face a critical lack of information and support, often resorting to local patient organizations for help. Patient organizations could support patients facing such odyssey by providing institutional information tools (such as websites and helplines), as well as social and psychological services [ 102 ]. Patient organizations also play a critical role in advocating for a more favorable policy environment for RDs.…”